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Abstract
Background: Randomized trials comparing the efficacy of standard endocrine therapy (ET) 
versus experimental ET+bevacizumab (Bev) in 1st line hormone-receptor positive metastatic 
breast cancer (MBC) patients have thus far shown conflicting results.
Patients and Methods: We pooled data from two similar Phase III randomized trials of ET +/− 
Bev (LEA and CALGB 40503) to increase precision in estimating treatment effect. Primary 
endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS), 
objective response rate (ORR), clinical benefit rate (CBR) and safety. Exploratory analyses were 
performed within subgroups defined by patients with recurrent disease, de novo disease, prior 
endocrine sensitivity or resistance, and reported grades 3–4 hypertension and proteinuria.
Results: The pooled sample consisted of 749 patients randomized to ET or ET+Bev. Median PFS 
was 14.3 months for ET versus 19 months for ET+Bev (unadjusted HR 0.77; 95% CI 0.66–0.91; 
p<0.01). ORR and CBR with ET and ET+Bev were 40 versus 61% (p<0.01) and 64 versus 77% 
(p<0.01), respectively. There was no difference in OS (HR 0.96; 95% CI 0.77–1.18; p=0.68). PFS 
was superior for ET+Bev for endocrine-sensitive patients (HR 0.68; 95% CI 0.53–0.89; p=0.004). 
Grade 3–4 hypertension (2.2 versus 20.1%), proteinuria (0 versus 9.3%), cardiovascular (0.5 
versus 4.2%) and liver events (0 versus 2.9%) were significantly higher for ET+Bev (all p<0.01). 
Hypertension and proteinuria were not predictors of efficacy (interaction test p=0.33).
Conclusion: The addition of Bev to ET increased PFS overall and in endocrine-sensitive patients 
but not OS at the expense of significant additional toxicity.
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Several preclinical and clinical studies have suggested that neoangiogenesis in general and 
high levels of VEGF in particular are linked to the development of resistance to hormonal 
therapy in breast cancer[1, 2]. These studies provide a rationale for the combination of 
endocrine therapy (ET) and antiangiogenic drugs in Metastatic Breast Cancer (MBC).
Two phase III randomized trials (LEA and Cancer and Leukemia Group B [CALGB] 40503) 
have compared standard ET with ET plus Bevacizumab (Bev)[3, 4], with conflicting results. 
We performed a pooled analysis with the aim to further understand the role of Bev in 
combination with ET in MBC and to identify subpopulations of patients that might benefit 
from this treatment strategy.
MATERIAL AND METHODS
Study design
This is a post-hoc analysis of individual data pooled from two randomized, multicenter, 
open-label, similarly designed phase III studies (LEA: GEICAM/2006–11_GBG_51 and 
CALGB 40503)[3, 4]. Each study was designed independently to compare the efficacy, in 
terms of progression-free survival (PFS), of ET alone versus ET+Bev as first line treatment 
for postmenopausal (or ovarian suppressed) MBC patients who were candidates for ET. 
Randomization was equally weighted and stratified as follows: in the LEA study by previous 
adjuvant ET with aromatase inhibitors [AI] (yes/no), number of involved sites (single/
multiple), presence of measurable disease (yes/no) and participating country (Spain/
Germany); and in the CALBG study by presence of measurable disease (yes/no) and 
disease-free interval from diagnosis to first recurrence/progression (<24 months/>24 
months).
Both studies were conducted in compliance with the International Conference on 
Harmonization Good Clinical Consolidated Guideline and were approved by independent 
ethics committees and Health Authorities. All patients provided written informed consent to 
participate.
In our pooled analysis, the primary objective was to compare PFS between the two arms in 
the total sample. Secondary objectives included comparing overall survival (OS), time to 
treatment failure (TTF), overall response rate (ORR), clinical benefit rate (CBR), response 
duration (RD), and safety. Exploratory objectives included testing for a treatment effect on 
all the efficacy endpoints above within the following subgroups: recurrent disease, de novo 
disease, endocrine-sensitivity and endocrine-resistance (defined as +/− 24 months without 
recurrence under ET in the adjuvant setting). We also wanted to determine whether grade 3–
4 hypertension and/or proteinuria correlated with PFS, OS and ORR in the total sample and 
by treatment arm.
Patients
Eligible patients were women at least 18 years old, postmenopausal (plus premenopausal 
with ovarian suppression in the CALGB study), with diagnosis of unresectable, locally 
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advanced or metastatic breast cancer, hormone-receptor positive (estrogen-receptor and/or 
progesterone-receptor >1%) and human epidermal growth factor receptor 2 (HER2) negative 
(or any HER2 status in the CALGB study). Eastern Cooperative Oncology Group 
performance status (ECOG PS) < 2 was required.
Exclusion criteria included prior therapy for metastatic disease (LEA study), ET or more 
than one line of prior chemotherapy for metastatic disease (CALGB study); rapid 
progressive disease requiring chemotherapy; central nervous system metastasis; uncontrolled 
arterial hypertension or clinically significant cardiovascular disease; history or evidence of 
hemorrhagic diathesis or coagulopathy with bleeding risk; major surgery within 28 days or 
minor surgery within 7 days of randomization; non-healing wounds; inadequate bone 
marrow, hepatic or renal functions; any other serious concomitant disorder; history of 
malignancy other than cervical or non-melanoma skin cancer adequately treated, or other 
cancers treated less than five years before study entry (LEA study) or with more than 30% 
risk of relapse (CALGB study).
Treatment
Standard ET was study-dependent and could be letrozole (2.5 mg/day) in both trials, 
fulvestrant (250 mg every 4 weeks) only in the LEA study or tamoxifen (20 mg/day) only in 
the CALGB study. Bev was administered as 15 mg/kg body weight every 3 weeks. 
Treatment continued until disease progression, unacceptable toxicity or withdrawn consent. 
Premenopausal patients had to undergo ovarian suppression either using luteinizing 
hormone-releasing hormone agonists or by oophorectomy.
Study procedures
Baseline assessments were performed within 28 days before study entry. These included 
chest and abdominal computed tomography (CT-scan), magnetic resonance or PET/CT-scan 
with intravenous contrast. Bone assessment (with bone-scan or PET/CT-scan) was 
mandatory in the CALGB study but was performed only if clinical suspicion in the LEA 
study. Hematology, biochemistry and urinalysis with proteinuria assessment (dip stick) were 
performed within 14 days before study inclusion.
Tumor assessments were performed, with the same method used at baseline, every 12 weeks 
until disease progression in the LEA study, and every 3 cycles until cycle 18 and then every 
4 cycles in the CALGB study. After confirmed disease progression, patients were followed 
for survival.
Adverse events were collected during the study treatment until 30 days of last dose of study 
drug. Serious adverse events related to study therapies were followed until resolution.
Statistical Analysis
Efficacy and safety analyses included all randomized patients who received at least one dose 
of study medication.
Kaplan-Meier method was used to estimate PFS, OS, TTF, and RD. The comparison of 
those endpoints between arms was performed using the logrank test. Cox regression models 
Martín et al. Page 4













were used to estimate unadjusted and adjusted hazard ratios and their 95% confidence 
intervals.
Multivariate analysis was carried out to assess the influence of the selected covariables 
(treatment arm, age, ECOG PS, disease-free interval, prior chemotherapy, prior ET, prior 
endocrine-sensitivity, type of ET, number of involved sites, sites of metastasis and disease 
measurability) on PFS. Robust sandwich level estimates based on a marginal model 
approach were utilized to correct standard errors in the Cox model, based on the methods of 
Lei, Win, and Weissfeld[5].
Logistic regression models were used to test the association of the above covariables with 
ORR and CBR, and to estimate odds ratios and their 95% confidence intervals.
Pearson χ2 or Fisher exact tests were used to assess the comparability of the two treatment 
arms in the incidence of relevant adverse events.
In order to ascertain whether the effect of grade 3–4 hypertension, proteinuria or both on 
efficacy differed by arm, we constructed Cox regression (for PFS and OS) and logistic 
regression (for ORR) models; these included an interaction term defined as the cross-product 
of the occurrence of the toxicity in question (yes/no) and arm (ET/ET+Bev). Additionally, 
models were constructed to test the toxicity effect within the ET+Bev arm. To adjust for bias 
that the probability of toxicity is associated with length of Bev treatment, we included a 
time-dependent covariable defined as less than versus greater than 4 cycles of therapy.
All statistical tests used in the analysis are two-sided. Data were analyzed using SAS 
Enterprise Guide (version 5.1) and R (version 3.1.2).
RESULTS
Seven hundred forty-nine patients comprised the pooled sample with 371 on the ET arm and 
378 on the ET+Bev arm. All these were evaluable for efficacy and safety (See Consort study 
flowchart).
Baseline characteristics were similar between arms (Table 1). Forty percent of patients had 
de novo advanced breast cancer and 59% recurrent disease, of whom 88% had disease that 
recurred more than 2 years after initial diagnosis. Half the sample had visceral metastases 
and 66.4% had measurable disease at baseline. Regarding prior treatments, 43.3% received 
prior chemotherapy and 50.7% prior adjuvant ET (21.8% with aromatase inhibitors).
Among patients with recurrent disease who received previous ET, 84% (N=146) in the ET 
arm and 82% (N=139) in the ET+Bev arm were endocrine-sensitive while, 11.5% (N=20) in 
the ET arm and 20.6% (N=36) in the ET+Bev arm were endocrine-resistant.
Adverse events
There was an increased incidence of related adverse events in the ET+Bev arm in 
comparison to the ET arm (44.2% vs 12.9%, p<0.0001), but without any additional 
unexpected event (supplementary material-SM1). The incidence of commonly related grade 
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3–5 adverse events in the ET+Bev versus ET arm was: hypertension (20.1% vs 2.2%, 
p<0.0001), proteinuria (9.3% vs 0.0%, p<0.0001), cardiovascular events (4.2% vs 0.5%, 
p=0.0006) and liver events (2.9 vs 0%, p=0.0005). Nine patients died while on study, 8 of 
them on the ET+Bev arm (1 due to pulmonary embolism, 3 of myocardial infarction, 1 of 
stroke, 2 due to cerebrovascular ischemia and one of liver failure), and one on the ET arm, 
whose cause was unknown.
Efficacy analysis
PFS—With a median follow-up of 34 months, a statistically significant difference in PFS 
was observed favoring the addition of Bev (HR for ET+Bev versus ET of 0.77; 95%CI: 
0.66–0.91; p= 0.0016). We made a comparison of restricted mean PFS times showing 
similar results (p=0.0043). Median PFS was 19 months (95% CI: 17.2–22.9 months) for ET
+Bev arm, and 14.3 months (95% CI: 12.6–17.0) for ET arm (Figure 1). After adjusting for 
baseline covariables, multivariate analysis maintained the statistically significant benefit of 
Bev in PFS (HR 0.76; 95% CI 0.64 – 0.89; p=0.0010) (SM2).
Subgroup analyses (Figure 2) found that the ET+Bev arm showed a significant improvement 
in PFS in the recurrent population (19.3 months in ET+Bev arm vs 12.3 months in ET arm; 
HR: 0.74, 95% CI 0.60–0.92; p=0.0059) and in patients with prior endocrine-sensitivity 
(18.5 months in ET+Bev arm vs 14.1 months in ET arm; HR: 0.68, 95%CI: 0.53–0.89; 
p=0.0042). The improvement in PFS in either de novo MBC patients or the endocrine-
resistant patients was not statistically significant (19.3 months in ET+Bev arm vs 14.6 
months in ET arm; HR 0.82; 95 % CI 0.63–1.06; p=0.1264 and 24.0 months in ET+Bev arm 
vs 14.4 months in ET arm; HR 0.73; 95% CI 0.40–1.32; p=0.2931, respectively).
Secondary Endpoints—ORR in patients with measurable disease and CBR in the total 
sample were significantly better in patients treated with ET+Bev (61% [n=250] and 77% 
[n=378]) than those with ET only (40% [n=247] and 64% [n=371]) with p values of <0.01 
and 0.01, respectively. De novo, recurrent and endocrine-sensitive patients obtained benefit 
in ORR and CBR with the addition of Bev but not the endocrine-resistant population. The 
addition of Bev to ET did not show a statistically significant benefit neither in TTF (HR 
0.90; 95% CI 0.77–1.04; p=0.1583) nor in RD (HR 0.82; 95% CI 0.62–1.08; p=0.1512); 
only patients with prior endocrine-sensitivity did slightly better with ET+Bev (HR 0.54; 
95% CI 0.33–0.89; p=0.0152). OS (SM3) did not show any difference with the addition of 
Bev to ET neither in the total sample (HR 0.96; 95% CI 0.77–1.18; p=0.6816; 47.2 months 
in ET arm vs 47.2 months in ET+Bev), nor in any of the subgroups analyzed.
See Table 2 for treatment effect on all efficacy endpoints in the total sample and the four 
subgroups of interest.
Table 3 shows the correlation of grade 3–4 hypertension and proteinuria with PFS, OS and 
ORR. In the ET+Bev arm, the occurrence of grade 3–4 hypertension was significantly 
asociated with better PFS (HR 0.66; 95% CI 0.48–0.89; p<0.01) and ORR (p=0.02), grade 
3–4 proteinuria with better PFS (HR 0.47; 95% CI 0.30–0.73; p<0.01), and grade 3–4 
hypertension/proteinuria with better PFS (HR 0.63; 95% CI 0.48–0.83; p<0.01), OS 
(p=0.02) and ORR (p<0.01) (SM4 Figure a, b and c). An interaction test to evaluate the 
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statistical validity of the relationship between the magnitud of Bev benefit and those 
toxicities in PFS was not statistically significant neither with hypertension nor with 
proteinuria or hypertension/proteinuria (p=0.33, p=na, p=0.35, respectively).
Considering these toxicities were infrequent in the ET arm and although the tests for 
interaction were not statistically significant, an analysis adjusted by their time of occurrence 
(within the first 4 cycles or after more than 4 cycles) were performed in the ET+Bev arm. 
They showed no correlation with PFS when they were occurring within the first 4 cycles 
(SM4 Figure d and e and f). We performed a landmark analysis at 4 months showing the 
same results (SM5 Figures a and b).
DISCUSSION
This pooled analysis demonstrates that the addition of Bev to ET as first-line therapy of 
hormone-receptor positive MBC significantly improves PFS. This difference is maintained 
when adjusting for other significant covariates and, therefore, seems to be a real finding. 
ORR and CBR were also significantly superior in patients treated with Bev. The addition of 
Bev, however, did not improve OS and was associated with a significant increase in relevant 
toxicities (hypertension, proteinuria, and cardiovascular events) and led to deaths due to 
toxicity. These results are very similar to those found in phase III trials in which 
chemotherapy plus bevacizumab was compared with chemotherapy alone in first-line MBC. 
The addition of bevacizumab to chemotherapy was associated with an increase in ORR and 
PFS, at the expense of significant toxicity[6]. The initial enthusiasm for antiangiogenic 
therapy in MBC following the results of the ECOG 2100 trial[7] was later tempered by the 
more modest results of other first and second-line bevacizumab-chemotherapy trials[8–10]. 
Furthermore, other oral antiangiogenic drugs[11–14] have also failed to improve the 
antitumor activity of chemotherapy in MBC.
Angiogenesis is one of the hallmarks of cancer and probably plays a significant role in the 
biology of MBC[15]. The reasons why bevacizumab therapy has not, then, succeeded in 
improving OS in MBC in spite of a clear improvement in PFS are still unknown. Many 
explanations have been suggested, including a rapid rebound of angiogenesis after 
discontinuation of therapy with selection of a resistant and more aggressive disease 
phenotype, and the implication of pro-angiogenic factors other than VEGF[16]. The inability 
of bevacizumab MBC studies to translate the PFS benefit into an OS benefit due to an 
inadequate power of the trials is unlikely, since a meta-analysis including thousands of 
patients has failed to show any signal of OS improvement[6].
Interestingly, GEICAM/2006–11_GBG51 and CALGB 40503 (Alliance) trials have shown a 
better than initially anticipated outcome of the control arm patients treated with endocrine 
therapy alone (median of around 14 months), data that should be taken into consideration for 
reference in modern endocrine therapy trials. The statistical assumption of these trials was a 
median PFS of 6–9 months, based on historical series that included HER2-positive patients. 
The increased PFS found in our trials is probably due to patient selection, (i.e: high 
proportion of patients with de novo metastatic disease and mainly hormone-receptor 
positive/HER2 negative tumors). An improved understanding of patient characteristics and 
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tumor biology in this selected first-line population could be of help for the design of future 
endocrine therapy trials.
Unfortunately, all the efforts aimed to find biological or clinical predictors of response to 
bevacizumab and other antiangiogenic drugs have been unsuccessful to date, as they have 
been in our pooled analysis. Our attempt to correlate bevacizumab-specific grade 3–4 
toxicities (i.e., hypertension and proteinuria) with efficacy was also unsuccessful. The 
apparent correlation between these toxicities and outcome found in our analysis was simply 
a reflection of the fact that patients with longer PFS have more probability to develop such 
toxicities due to longer exposure to bevacizumab. As a matter of fact, when we adjust the 
analysis by the time of occurrence of these toxicities, we see that an early onset of grade 3–4 
hypertension or proteinuria was not correlated with better PFS.
The two bevacizumab studies discussed here were designed when the data from the modern 
CDK 4–6 inhibitors were not available. The bevacizumab data are today of less relevance in 
practical terms, since endocrine therapy plus a CDK 4/6 inhibitors rather than endocrine 
therapy alone is considered the standard of care firt-line therapy for these patients.
CONCLUSIONS
In summary, our pooled analysis found that adding bevacizumab to first-line endocrine 
therapy of MBC significantly improves PFS and ORR/CBR without any significant impact 
on OS and at the cost of significant toxicity. On the basis of this analysis, and unless strong 
biological predictors of response are found, the combination of endocrine therapy plus 
bevacizumab should not be recommended in the treatment of hormone-receptor positive/
HER2 negative advanced breast cancer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Bevacizumab plus endocrine therapy increased progression-free survival 
overall.
• Bevacizumab plus endocrine therapy does not increased overall survival.
• This combination adds significant toxicity.
• This should not be recommended for 1st line HR+ /HER2- advanced breast 
cancer.
• Hypertension and proteinuria are not predictive of bevacizumab efficacy.
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Figure 1. Progression-free Survival
Abbreviations: ET, Endocrine Therapy; ET+Bev, Endocrine Therapy + bevacizumab; PFS, 
progression-free survival.
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Figure 2. Forest plot of subgroup analysis for progression-free survival
Abbreviations: ET, Endocrine Therapy; ET+Bev, Endocrine Therapy + bevacizumab; HR, 
hazard ratio; DFI, disease-free interval.
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Table 1.
Patient and baseline tumor characteristics
Characteristic Control ET Experimental ET+Bev
n=371 n=378
Age
 Median (range) 62 (29–87) 60.5 (25–85)
ECOG PS
 0 66.3% 68.5%
 1 32.9% 30.9%
 2 0.5% 0.3%
 Not Available 0.3% 0.3%
Disease status at diagnosis
 De novo advanced disease 40.7% 39.7%
 Recurrent disease 59.0% 60.3%
   ≤1 year 2.2% 4.0%
   (1–2) years 3.0% 5.0%
   >2 years 53.3% 51.3%
   Not Available 0.5% 0.0%
 Not Available 0.3% 0.0%
Prior chemotherapy
 No 36.1% 37.3%
 Yes 43.1% 43.4%
 Not Available 20.8% 19.3%
Prior adjuvant ET
 No 48.5% 45.8%
 Yes 49.6% 51.1%
 Not Available 1.9% 3.1%
Type of prior ET
 No prior ET 48.5% 45.8%
 Tamoxifen only 25.9% 29.6%
 AI (+/−Tamoxifen) 23.2% 20.4%
 Other 0.5% 1.1%
 Not Available 1.9% 3.1%
Number involved sites
 Single 34.2% 36.8%
 Multiple 65.5% 63.2%
 Not Available 0.3% 0.0%
Site of metastasis
 Soft tissue only 8.1% 5.8%
 Bone+/−Soft tissue 41.0% 43.4%
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Characteristic Control ET Experimental ET+Bev
n=371 n=378
 Visceral 50.4% 50.3%
 Not Available 0.5% 0.5%
Disease measurability
 Non-measurable 33.4% 33.9%
 Measurable 66.6% 66.1%
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; ET, Endocrine Therapy; ET+Bev, Endocrine Therapy + 
bevacizumab; AI, Aromatase Inhibitor.
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Table 2.






























































































p-value <0.01 <0.01 <0.01 <0.01 0.54
Note: HR < 1.0 indicates ET+Bev benefit; OR > 1.0 indicates ET+Bev benefit.
Abbreviations: ET, endocrine therapy; PFS, progression-free survival; OS, overall survival; TTF, time to treatment failure; RD, response duration; 
ORR, overall response rate; CBR, clinical benefit rate; HR, hazard ratio.













Martín et al. Page 17
Table 3.



















































p-value 0.06 Na 0.06 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01


























p-value 0.07 Na 0.07 0.07 0.05 0.02 0.01 0.05 <0.01


























p-value 0.21 Na 0.21 0.02 0.06 <0.01 <0.01 0.01 <0.01
pint-value 0.66 na 0.80
Note: Na = zero toxicity events in the ET arm.
Abbreviations: ET, Endocrine Therapy; ET+Bev, Endocrine Therapy + bevacizumab; HT: hypertension; Prot: proteinuria; na: not available; pint-
value: p-value of interaction test between HT/Prot and treatment arm. PFS, progression-free survival; OS, overall survival; ORR, overall response 
rate.
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